RT Journal
A1 Fourtounas C
T1 VItamin d therapy and cardiac function in chronic kidney disease
JF JAMA
JO JAMA
YR 2012
FD June 6
VO 307
IS 21
SP 2253
OP 2253
DO 10.1001/jama.2012.4168
UL http://dx.doi.org/10.1001/jama.2012.4168
AB 
To the Editor: The Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial by Dr Thadhani and colleagues1 failed to show any improvement in left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) after daily oral administration of paricalcitol for 48 weeks. Similar outcomes have been reported in other prospective studies of patients with CKD receiving erythropoiesis-stimulating agents.2- 3